Select Equity Group Foundation Awards $71,370 Grant to Michael Mosier Defeat DIPG Foundation

Michael Mosier Defeat DIPG® Foundation is pleased to announce the exciting news that it has been awarded a $71,370 grant by Select Equity Group Foundation.  This is the second year of generous support from Select Equity Group Foundation, after an initial 2017 grant of $79,300 to support the Foundation’s DIPG research initiatives.

The 2018 Celebration Grant will play a critical role in supporting the Foundation’s growth through infrastructure expansion.  Since its creation in 2015, the Foundation has seen substantial increase in revenue, as well as geographic expansion of its operations through the addition of chapters across the country.  By strengthening its operations through staff hiring and further development of corporate partnerships, the Foundation will be even better situated to expand its impact on research funding to transform our understanding of the deadliest pediatric brain cancer, diffuse intrinsic pontine glioma (DIPG).

Select Equity Group Foundation’s mission is to make a positive impact by actively engaging all employees in identifying and supporting charitable organizations of excellence.  Select Equity Group Foundation uses a democratic process as the primary mechanism for its grantmaking, whereby its employees nominate charities for consideration.  Select Equity Group Foundation conducts a rigorous research process, including application by invitation and discussions with leadership before an award can be considered.  To date, Select Equity Group Foundation has awarded more than $20 million in grants to nonprofit organizations in a range of areas.

Tracy Thomas, Associate General Counsel at Select Equity Group, championed Michael Mosier Defeat DIPG Foundation during their annual celebration. Tracy also volunteered for the Foundation this year at our 2nd Annual Defeat DIPG Dream Big Gala. We greatly appreciate Tracy’s efforts to share with her colleagues the critical need for investment in finding a cure for this devastating disease.  We also thank Robert Wilson, Executive Director of Select Equity Group Foundation, as well as all of the Select Equity Group employees who supported the award of this grant.

Michael Mosier Defeat DIPG® Foundation is a 501(c)(3) nonprofit organization that supports research initiatives designed to find a cure for DIPG brain tumors.  DIPG impacts hundreds of children each year in the U.S. alone, typically between the ages of 4 – 11 years old. These kids face a median survival of 9 months from diagnosis and overall survival of less than 1%.

The Defeat DIPG Foundation Board of Directors makes funding decisions, after consideration of recommendations from its Scientific Advisory Council (SAC).  The SAC consists of preeminent doctors in the field of brain cancer and is led by Chair Darell D. Bigner, M.D., Ph.D., Director of The Preston Robert Tisch Brain Tumor Center at Duke University.  Defeat DIPG Foundation has experienced significant growth since its creation in 2015, with the addition of five Defeat DIPG® Network chapters across the United States in Illinois (Anthony’s Avengers Defeat DIPG® Foundation), Pennsylvania (Addison Grace Defeat DIPG® Foundation), Texas (Connor Man Defeat DIPG® Foundation), and two in Washington (Avery Huffman Defeat DIPG® Foundation and Vivian Rose Weaver Defeat DIPG® Foundation).

There has been a significant increase in research focused on DIPG, including notable advancements of knowledge about the biology of the disease just in the past five years.  With increased access to tumor tissue, more sophisticated technology, and greater information sharing between institutions, there is hope that children facing DIPG will soon have more options and hope for extended survival.

To learn more, visit DefeatDIPG.org.

2nd Annual Defeat DIPG Dream Big Gala Raises Over $435,000

The 2nd Annual Defeat DIPG Dream Big Gala, presented by DARCARS Automotive Group, took place on Saturday, November 3, 2018, at the Hyatt Regency Bethesda.  Thanks to our sponsors, attendees and other supporters, we are thrilled to report that we raised over $435,000. We are Dreaming Big for a cure for DIPG brain cancer, and these funds will help us make that dream a reality.

We looked out on a room of 450 people at the gala, and we felt a powerful sense of hope and determination.  With so many banding together to take on this horrible disease, we know that progress will be made.

We thank every DIPG family who allowed us to honor their child and especially those who attended, even knowing how difficult it can be on your already broken hearts. Three amazing DIPG families stood on stage and shared their stories with our guests, and it was their willingness to open their hearts that made the whole night.  We give our heartfelt thanks to Lauren Gibson, Tammi & Jason Carr, and Rich & Nancy Engler.  Dara, Chad, and Luke are an inspiration to us all.

Mitch Albom was unable to join us in person, but he took the time to send a powerful video about the beautiful Chika Jeune who fought DIPG so bravely.  The love he and his wife had for Chika shined through, and we were honored to have her story as part of the event.

We thank every person who spent the night at the gala, sponsored DIPG family tickets, bought auction items, and otherwise donated to our mission.

We thank our Gala Host Committee that poured endless hours into making this event a success:  Jacqueline Chan, Jenny Ellickson, Amy Elliott, Marguerite Laurent, Lori McGill, Amanda Posner, Amy Rogstad, and Jennifer Saulino.

We thank our Event Emcee Tommy McFly (TommyShow.com) and our generous sponsors:

  • PRESENTING “VISIONARY” SPONSOR:  DARCARS Automotive Group
  • PLATINUM “HOPE” SPONSORS:  PhRMA, [D3] District Design + Development, and NextGen LED
  • BAR “STARGAZER” SPONSOR:  Total Wine & More
  • GOLD “IMAGINE” SPONSORS:  Bayou Bakery, Good Stuff Eatery, and Hyatt Regency Bethesda
  • TABLE SPONSORS:  Ceros Financial Services, Inc., Children’s National Medical Center, Debevoise & Plimpton, Ernst & Young, FTI, Jack Silverman, DDS, K&L Gates, Next Level Rentals & Management, and Friends from Covington & Burling LLP.
  • IN-KIND SPONSORS:  CONTEND; Electra Entertainment; Sarah Marcella Creative; Barry Artistic Media Design; and BaseCamp DC
  • SUPPORTERS: Cynthia Schnedar & Mark Polston; Lewis Asset Management; Sports and Orthopaedic Therapy Services; Central Maryland Oral and Maxillofacial Surgery, P.A.; Dominos; Scott Bilbrey; and Pepco

The Live Auction was run by the talented auctioneer Ernie Rogers and his team, who entertained the crowd and helped us raise some serious funds for DIPG research!  Thank you to all who donated incredible Live Auction packages, including Lauren Phillips & Family; Maggie O’Neill; Chef Michael Friedman of The Red Hen and All-Purpose DC; Chef Erik Bruner-Yang; Total Wine & More; Jackson Family Wines, and Hyatt Hotels.

We thank Michael for being our light and inspiration, along with each and every child who has confronted this disease.  Yes, we Dream Big.  But these kids deserve that and so much more.  Together, we will Defeat DIPG.

***

Save the Date:  the 3rd Annual Defeat DIPG Dream Big Gala will be on Saturday, October 26, 2019, at the North Bethesda Marriott.

 

 

Defeat DIPG Makes Grant to Oncoceutics to Support Development of ONC201

Michael Mosier Defeat DIPG Foundation has made a grant to support development of ONC201, an experimental drug currently being tested to treat DIPG.  We have made this grant in collaboration with the Musella Foundation, The Cure Starts Now, Cancer Commons, and xCures.

Our objective in funding this program is to increase the availability of ONC201 for DIPG patients.  The first goal is to facilitate enrollment in ONC201 clinical trials for any patient who is eligible for a trial.  But we also recognize that many DIPG patients will not be able to enroll in a trial.  For those patients, our goal is to assist them in getting access to ONC201 through an expanded access program where medically appropriate.

Oncoceutics has issued the following press release to announce the grant.

Philadelphia, PA (September 10, 2018) – Oncoceutics, Inc. announced the receipt of a Small Business Innovation Research (SBIR) Phase IIB Bridge Award from the National Cancer Institute (NCI).  The NCI SBIR Bridge Award will allow Oncoceutics to expand and accelerate its clinical trials evaluating ONC201 in patients with a specific type of lethal brain cancer called H3 K27M-mutant glioma.

The awarded project, “Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High-Grade Glioma” (grant number 2R44CA192427-04), builds upon the work supported by previous NCI SBIR Fast-Track grant that supported Oncoceutics’ effort demonstrating the activity of ONC201 in high-grade gliomas, including those with the H3 K27M mutation that is commonly present in the midline region of the brain. Each year, the NCI’s SBIR Development Center presents the Phase IIB Bridge Award to a select number of companies based on NCI and external expert review of the scientific merits and commercial potential of the technology. Awardees are required to allocate third-party investment to match the Bridge funding prior to submitting the funding application which occurred in mid-2017. The NCI Bridge Award will provide $3 million to Oncoceutics to advance the clinical development of ONC201 over the next 3 years.

Patients with H3 K27M-mutant glioma often have significant neurological symptoms from their disease and lack proven therapeutic options other than palliative radiotherapy. However, emerging clinical results have shown that some patients treated with single agent ONC201 have stable disease, have had their tumor shrink, and/or have had improvements in neurological symptoms, such as paralyses of peripheral and cranial nerves. This has been observed in adults and children treated with ONC201, including children with diffuse intrinsic pontine glioma (DIPG), a type of high-grade glioma that almost uniformly (80-90%) harbors the H3 K27M mutation.

“We are extremely pleased to see continued support from the NCI for the ONC201 clinical program in H3 K27M-mutant gliomas based on the clinical activity observed in our Phase II study supported by the Fast-Track SBIR grant,” said Patrick Wen, MD, Director, Center For Neuro-Oncology, Dana-Farber Cancer Institute.

“The emerging clinical experience with ONC201 to treat gliomas at our institution and other leading cancer centers around the country is exciting,” added said Yazmin Odia, MD MS, Lead Physician of Medical Neuro-Oncology, Miami Cancer Institute. “The dismal prognosis of midline gliomas and the dearth of therapeutic options means that this therapy could be practice-changing for neuro-oncology. We are eager to follow up on the radiographic and clinical improvements in biomarker-defined patients that we have seen with ONC201 as a single agent in our ongoing clinical trials. Future co-operative group efforts between NRG Oncology and the Children’s Oncology Group to test this drug in children and adults with newly diagnosed H3 K27M-mutant midline gliomas are in the planning process.”

In addition to the support from the NCI, Oncoceutics has also received support from The Musella Foundation, a non-profit organization that helps brain tumor patients through education, advocacy, and financial support. The Musella Foundation has supported Oncoceutics’ development of ONC201 in high-grade gliomas for several years from bench to Phase II clinical trials. The Musella Foundation, in collaboration with Cancer Commons, Michael Mosier Defeat DIPG Foundation, The Cure Starts Now Foundation and xCures, has committed to contribute at least $1 million in hopes of accelerating the development of ONC201.

“Having represented and supported brain tumor patients’ interests for several decades, it has been frustrating to experience the failures of new treatments that have been developed to impact the outcome of this disease,” said Al Musella, Founder and President of the Musella Foundation. “As highlighted in a recent ODAC meeting, the FDA, in collaboration with the NCI, is tasked with determining whether a molecular target is or is not considered substantially relevant to the growth or progression of pediatric cancer. We are excited to work with Oncoceutics that is developing a molecularly targeted agent, ONC201, that demonstrates the potential to advance the concept of Precision Medicine in patients that harbor the H3K27M mutation, a genetic aberration that is considered substantially relevant for the outcome of this disease.  We are looking forward to contribute to making this drug available for as many patients as possible.”

About Oncoceutics

Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds that selectively target G protein-coupled receptors for oncology. The first lead compound to result from this program is ONC201, an orally active DRD2 small molecule antagonist that is well-tolerated and effective against advanced cancers. The company completed a successful Phase I study in solid tumors and has underway a number of Phase I/II and Phase II clinical programs in both solid and hematological malignancies. Oncoceutics and collaborative groups have received more than $7 million in grants over the last two years, including grants from the National Cancer Institute, the U.S. Food and Drug Administration, the Pennsylvania Department of Health, and The Musella Foundation. In addition, outside interest in the company’s portfolio has resulted in several R&D alliance agreements between Oncoceutics and leading comprehensive cancer centers, including The University of Texas MD Anderson Cancer Center and the Fox Chase Cancer Center. The company has established a robust intellectual property position, including several issued patents. Visit oncoceutics.com for more information.

About The Musella Foundation

The Musella Foundation For Brain Tumor Research & Information, Inc is a 501(C)3 nonprofit public charity dedicated to helping brain tumor patients through emotional and financial support, education, advocacy and raising money for brain tumor research. Visit virtualtrials.com for more information.

About Cancer Commons

Cancer Commons is a nonprofit collaborative of patients, physicians, and scientists, dedicated to improving patient outcomes by tightly coupling clinical research and care. We arm patients and their physicians with the knowledge they need to achieve the best possible outcomes, help them access the relevant treatments and trials, and track their results to continuously learn. Vistit cancercommons.org for more information.

About Michael Mosier Defeat DIPG Foundation

Michael Mosier Defeat DIPG Foundation is committed to finding a cure for brainstem tumors known as diffuse intrinsic pontine gliomas (DIPG).  Nearly every day one child in the United States is diagnosed with DIPG and another child dies from it. The Foundation seeks to make a difference and defeat DIPG both by raising awareness of DIPG and by providing funding for research into effective treatments for DIPG. Visit defeatdipg.org for more information.

About The Cure Starts Now Foundation

The Cure Starts Now Foundation is a 501(c)3 nonprofit organization with international chapters in nearly 40 locations around the world.  It is has funded universal cancer cure strategies starting with cancers such as DIPG and organizes the biennial International DIPG Symposium showcasing innovative research methods. You can learn more at www.thecurestartsnow.org.

About xCures

xCures is developing an AI-based methodology and platform to run ‘Virtual Trials’, which continuously learn from the clinical experiences of all patients, on all treatments, all the time. Each patient’s treatment regimen is adaptively planned by a ‘Virtual Tumor Board’ to optimize their individual outcome, and these plans are coordinated across the whole patient population to maximize collective learning. Visit xcures.com for more information.

 

Washington Capitals Defenseman John Carlson Raises Over $115,000 for DIPG Research on Day with the Stanley Cup

Michael Mosier Defeat DIPG Foundation had a lot to celebrate on this year’s 4th of July, with over $115,000 raised to fund research for a cure for DIPG, thanks to the generosity of Washington Capitals player John Carlson and his wife, Gina.

In June, the Washington Capitals won the first Stanley Cup in franchise history.  Following hockey tradition that has developed over the years, each team member gets the chance to spend a day with the prized Stanley Cup.  John Carlson, a star defenseman on the Washington Capitals, chose to spend part of his day with the Stanley Cup to benefit Michael Mosier Defeat DIPG Foundation.

John Carlson was the highest-scoring NHL defenseman during the 2017-18 regular season and playoffs, and he has spent his whole career with the Washington Capitals since he joined the team as a first-round draft pick in 2008. Caps fans were thrilled to learn that John recently signed a new eight-year contact with the Capitals and will be continuing as a key contributor to the team’s success.

Carlson, along with his family, brought the Stanley Cup to a fundraiser organized by Michael Mosier Defeat DIPG Foundation on the grounds of Community Partner Bethesda Row.  Over 1,000 fans gathered to view the Cup and to continue the celebration of the Capitals’ victory.  Grant Paulsen, who hosts NBC’s pre- and post-game Capitals coverage and Grant and Danny on 106.7 The Fan, did an outstanding job as the emcee of the event. General admission tickets included free food and entertainment, along with a view of the Stanley Cup. Limited VIP tickets were also available and gave fans the exciting opportunity of a photo with John Carlson and the Stanley Cup.  In the first ten minutes of ticket sales, over $40,000 of tickets were purchased.  The event sold out entirely in 3 days.

The Capitals released a phenomenal video that captures some of John Carlson’s day with the Stanley Cup.  In addition to the fundraiser at Bethesda Row, Carlson visited a fire department, Children’s National Medical Center, and a Kenwood neighborhood parade (whose participants also generously contributed to Defeat DIPG Foundation as part of their event).

Beyond the significant funds raised to help find treatments for children fighting this devastating childhood brain cancer, this event offered a unique opportunity to raise awareness of DIPG to a broad audience. News outlets including Fox 5 DCNHL.com, WTOP, Bethesda Magazine, and featured the event and the work of the Foundation.

The Foundation also had the opportunity to partner with new sponsors who were valued contributors to the event.  Community Partner Bethesda Row was an essential partner and co-host. Mamma Lucia Restaurants provided complimentary food for all attendees, gift cards for VIP attendees, and a donation of all proceeds from beverages sold at the event; Medium Rare donated food and beverages for the VIP tent; and Waldorf Toyota was a generous financial supporter. Thank you to Sarah Marcella Creative for generously donating time and services for the VIP photography, Harry Greenspun for general event photos, and Everything Entertainment for their photo booths. We also are deeply grateful for the support of the Montgomery County Police Department for their support.

SaveSave

SaveSave

SaveSave

SaveSave

SaveSave

SaveSave

Vivian Rose Weaver Defeat DIPG Foundation Announces $1 Million Donation to DIPG Research, $2 Million 2018 Goal & Lemon Face Challenge

Vivian Rose Weaver Defeat DIPG Foundation, in Husum, WA, is excited to announce that a generous anonymous supporter has donated $1 million that will be used towards DIPG-specific research funding in 2018. Vivian Rose Weaver Defeat DIPG Foundation was inspired by, and established in honor of, Vivian Rose Weaver, who is a smart, articulate, funny, sweet, thoughtful, imaginative, precocious, 3.5-year-old little girl who was diagnosed in February 2018 with a brainstem tumor called diffuse intrinsic pontine glioma (DIPG). DIPG is the deadliest form of pediatric brain cancer.  Vivian Rose Weaver Defeat DIPG Foundation is a chapter of Michael Mosier Defeat DIPG Foundation and part of Defeat DIPG Network.

Co-Founders Katie and Simon Weaver are focusing on Vivian’s care, and her little sister Lucie, as their top priority.  But they are also already making a substantial impact on the field of DIPG research by raising crucial funds to find a cure.

And the Weavers are not stopping with $1 million.

Vivian Rose Defeat DIPG Foundation would like to raise an additional $1 million this year, with an overall 2018 goal of $2 million raised for research.  To put these numbers in perspective, the overall funding for DIPG research in any given year has typically been – at most – $2-5 million in a year.  This is .0005% of the total funding for cancer research.

The funds raised will support the most promising DIPG research initiatives through the Defeat DIPG grantmaking process.  All grant applications go through a rigorous review by a preeminent group of brain tumor experts that serve on the Defeat DIPG Scientific Advisory Council to ensure funds are used efficiently for initiatives with high scientific merit.

We call on everyone to join this effort.  And, it couldn’t be easier.

An initiative called the #LemonFaceChallenge, started by a little girl named Aubreigh who is also fighting DIPG, has triggered worldwide attention to DIPG brain tumors.  It has been heartening to see professional sports teams and coaches, members of the media, and so many others participate. The challenge is in the mold of the Ice Bucket Challenge, which raised $115 million in the summer of 2014 for ALS (amyotrophic lateral sclerosis or Lou Gehrig’s disease), dramatically increasing available funds for research for that disease.

Vivian Weaver, who inspired the $1 million donation to DIPG research, along with her parents Simon and Katie, are asking you to help us generate even more funds to find a cure.  Vivian and the Weaver family are taking #LemonFaceChallenge and calling on you to keep the challenge going.

Here’s what you do:

  1. Take a video of yourself, your kids, your friends, your co-workers – anyone you can who will participate in the #LemonFaceChallenge, which means you take a big bite out of a lemon wedge!
  2. Tell them you are donating to Defeat DIPG and doing the video to find a cure for children facing DIPG, the deadliest form of pediatric brain cancer.
  3. Share the video and tag as many friends as you can and ask them to take the challenge.
  4. Donate to Vivian Rose Defeat DIPG Foundation through the Facebook fundraiser pinned to the top of their Facebook page (which has no processing fees), through their website, or through any member of Defeat DIPG Network.

DIPG is the deadliest form of pediatric brain cancer, with a median survival from diagnosis of 9 months and a near 0% survival overall. DIPG typically strikes children between ages four and eleven. Because of its location in the brainstem where all motor activity is controlled, DIPG is inoperable. The disease progresses by taking over a child’s motor functions one-by-one, typically starting with vision and balance problems, before moving to partial paralysis, followed by the inability to chew, speak, swallow, move and eventually breathe – all of this while the child remains mentally intact.

Raising $2 million through this initiative is a lofty goal.  But, if kids like Vivian can fight hard every single day to beat this brain tumor, we can fight just as hard to make sure there are effective treatments for kids like her.

By supporting Defeat DIPG Network, you have the opportunity to move the needle and help us save lives of our precious children.  Together, we will substantially increase research funding while also greatly increasing awareness of this devastating disease.

Michael Mosier Defeat DIPG Foundation Announces New Washington Chapter Honoring Three-Year-Old Vivian Rose Weaver Who Is Fighting DIPG Brain Tumor

Michael Mosier Defeat DIPG® Foundation, a nonprofit whose mission is finding a cure for the deadliest pediatric brain cancer, DIPG (diffuse intrinsic pontine glioma), announced today the addition of a second chapter in Washington State, to its Defeat DIPG® Network:  Vivian Rose Weaver Defeat DIPG® Foundation.  Vivian Rose Weaver Defeat DIPG Foundation is founded in honor of Vivian Rose Weaver, a 3.5-year-old girl from Husum, Washington, who has been battling a DIPG brain tumor for nearly 3 months.

The new chapter adds to Defeat DIPG Network’s existing presence across the United States, in Maryland, Washington, D.C., and Kansas as Michael Mosier Defeat DIPG Foundation, in Illinois as Anthony’s Avengers Defeat DIPG® Foundation, in Pennsylvania as Addison Grace Defeat DIPG® Foundation, in Texas as Connor Man Defeat DIPG® Foundation and in Washington as Avery Huffman Defeat DIPG® Foundation. The Defeat DIPG Network has raised over $2 million for DIPG research in 2.5 years.

Vivian Rose Weaver was diagnosed with a brainstem tumor on February 1, 2018. With great bravery, 3-year-oldVivian has faced a number of difficult medical procedures over the past few months, including a biopsy and 30 rounds of radiation treatment that required daily sedation. Vivian’s family describes her as a smart, articulate, funny, sweet, thoughtful imaginative, and precocious little girl who is full of love for life and people.  Fortunately, Vivian has been doing well and is virtually symptom free.

“Learning that our little girl has DIPG was devastating – a worst case scenario,” says Vivian’s mother Katie Weaver, who will serve as the Director of Vivian Rose Weaver Defeat DIPG Foundation. “We are launching a multi-pronged attack on this disease, through our prayers for God’s healing, by finding the most promising treatments we can for Vivian, and now through our efforts to raise fund for essential research for a cure.”

Jenny and Mark Mosier created Michael Mosier Defeat DIPG Foundation in June 2015 to fund DIPG research and promote awareness of the disease, after the passing of their 6-year-old son Michael. With its geographic expansion and growth of existing initiatives, the Foundation expects to continue to increase its capacity to fund essential childhood cancer research.

In December 2017, the Foundation announced over $1 million in DIPG-specific research funding, in partnership with The ChadTough Foundation. Michael Mosier Defeat DIPG Foundation works with a preeminent Scientific Advisory Council of brain tumor experts that advises its Board of Directors on how to maximize its resources to fund research for a cure for DIPG. The Foundation will soon begin accepting grant applications for 2018, and expects to announce another round of funding before the end of 2018.

The Mosier, Gaskin, Holl, Huffman, Olympia, and Weaver families will work to grow the already powerful base of support in each of their communities, and to honor and unite all children and families who have had to confront this disease.

“Joining together with the Weaver family – who are in the midst of the difficult fight against this disease with their precious daughter Vivian – even further motivates our efforts and our urgency to find a cure for DIPG,” says Jenny Mosier, Executive Director of Michael Mosier Defeat DIPG Foundation. “After experiencing firsthand the cruel impact DIPG inflicted on our own children, we are laser focused on our mission to eradicate this disease.”

DIPG is the deadliest form of pediatric brain cancer, with a median survival from diagnosis of 9 months and a near 0% survival overall. DIPG typically strikes children between ages four and eleven. Because of its location in the brainstem where all motor activity is controlled, DIPG is inoperable. The disease progresses by taking over a child’s motor functions one-by-one, typically starting with vision and balance problems, before moving to partial paralysis, followed by the inability to chew, speak, swallow, move and eventually breathe – all of this while the child remains mentally intact.

For decades, treatment for DIPG has remained the same and has been ineffective. The entire amount spent annually on DIPG research – approximately $3 – 5 million – is less than 0.0005% of the total funding for cancer research.  In just the past few years, due to better medical technology and increased access to tumor tissue, researchers have made real advances in their understanding of this disease.  There is finally hope for progress in finding a cure.

Get a printer-friendly copy of this release here.

SaveSave

SaveSave

SaveSave

SaveSave

Michael Mosier Defeat DIPG Foundation Announces New Pennsylvania Chapter: Addison Grace Defeat DIPG Foundation

Michael Mosier Defeat DIPG Foundation, a nonprofit whose mission is finding a cure for the deadliest pediatric cancer, DIPG (diffuse intrinsic pontine glioma), announced today the addition of a chapter in Mechanicsburg, Pennsylvania, to its Defeat DIPG® Network:  Addison Grace Defeat DIPG Foundation. The new chapter adds to Defeat DIPG Network’s existing presence across the United States, in Maryland, Washington, D.C., and Kansas as Michael Mosier Defeat DIPG Foundation, in Illinois as Anthony’s Avengers Defeat DIPG Foundation, in Texas as Connor Man Defeat DIPG® Foundation and in Washington as Avery Huffman Defeat DIPG® Foundation. The Defeat DIPG Network has raised over $2 million for DIPG research in 2.5 years.

The Pennsylvania chapter, which will operate as Addison Grace Defeat DIPG Foundation, is founded in memory of Addison Grace Holl. Addison was a fun loving seven-year-old when she was diagnosed with DIPG. She lived for almost two years after diagnosis before she passed away a month before her ninth birthday. In her short life, she touched many lives and her spirit continues to live on through acts of kindness. She was taken decades before she should have been, and her loved ones are determined to make a difference in the fight against DIPG. Addison’s mother, Kim Holl, will serve as the Director of Addison Grace Defeat DIPG Foundation.

Jenny and Mark Mosier created Michael Mosier Defeat DIPG Foundation in June 2015 to fund DIPG research and promote awareness of the disease, after the passing of their 6-year-old son Michael. With its geographic expansion and growth of existing initiatives, the Foundation expects to continue to increase its capacity to fund essential childhood cancer research.

In December 2017, the Foundation announced over $1 million in DIPG-specific research funding, in partnership with The ChadTough Foundation. Michael Mosier Defeat DIPG Foundation works with a preeminent Scientific Advisory Council of brain tumor experts that advises its Board of Directors on how to maximize its resources to fund research for a cure for DIPG. The Foundation will soon begin accepting grant applications for 2018, and expects to announce another round of funding before the end of 2018.

The Mosier, Gaskin, Holl, Huffman, and Olympia families will work to grow the already powerful base of support in each of their communities, and to honor and unite all children and families who have had to confront this disease.

“There is power in joining together with other passionate families who are similarly dedicated to finding a cure for this devastating disease,” says Jenny Mosier, Executive Director of Michael Mosier Defeat DIPG Foundation. “We have seen firsthand the impact DIPG inflicted on our own children, so we are laser focused on pushing the field forward so in the future kids will have viable treatment options and hope for long term survival.”

DIPG is the deadliest form of pediatric brain cancer, with a median survival from diagnosis of 9 months and a near 0% survival overall. DIPG typically strikes children between ages four and eleven. Because of its location in the brainstem where all motor activity is controlled, DIPG is inoperable. The disease progresses by taking over a child’s motor functions one-by-one, typically starting with vision and balance problems, before moving to partial paralysis, followed by the inability to chew, speak, swallow, move and eventually breathe – all of this while the child remains mentally intact.

For decades, treatment for DIPG has remained the same and has been ineffective. The entire amount spent annually on DIPG research – approximately $3 – 5 million – is less than 0.0005% of the total funding for cancer research.  In just the past few years, due to better medical technology and increased access to tumor tissue, researchers have made real advances in their understanding of this disease.  There is finally hope for progress in finding a cure.

Get a printer-friendly copy of this release here.

SaveSave

SaveSave

SaveSave

SaveSave

SaveSave

Defeat DIPG Giving Tuesday Initiative Raises Over $104,000

We express our deep gratitude to the amazing supporters of Defeat DIPG® Network and the fight to find a cure to the deadliest brain cancer: DIPG brain tumors.
 
We are so thrilled to announce the results of our #Give2DefeatDIPG initiative on November 28th:
 
🌟 Over $104,000 for DIPG research 🌟
🌟 Over 730 different donors 🌟
 
You rallied with us to show your commitment to changing the outcome for kids facing DIPG. We stand together in taking action to show we will not accept the grim statistics and lack of options.
 
Our initial goal for the day was to raise $30,000 that would be matched by our sponsors to total $60,000. We are deeply grateful for the tremendous outpouring of support that helped us far exceed this goal.
 
We want to once again thank our generous matching sponsors who were essential to our success on Giving Tuesday. Thank you to the William & Mildred Kaplan Charitable Foundation, Tough Like Jack Foundation, Anndreya & Zach Harris, and an anonymous donor for committing the initial $30,000 in matching funds. And thank you to a generous family of one of Michael’s classmates and two more anonymous donors who added another $10,000 of matching after we reached our initial goal.
 
We work to honor all children who have faced this devastating disease. And we work for the children who will be diagnosed in the future. Together, we WILL Defeat DIPG.
 
Thank you from your Defeat DIPG® Network friends.
 
Michael Mosier Defeat DIPG Foundation
Anthony’s Avengers Defeat DIPG Foundation
Avery Huffman Defeat DIPG Foundation
Connor Man Defeat DIPG Foundation